Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL
Guièze R., Robbe P., Clifford R., de Guibert S., Pereira B., Timbs A., Dilhuydy M-S., Cabes M., Ysebaert L., Burns A., Nguyen-Khac F., Davi F., Véronèse L., Combes P., Le Garff-Tavernier M., Leblond V., Merle-Béral H., Alsolami R., Hamblin A., Mason J., Pettitt A., Hillmen P., Taylor J., Knight SJL., Tournilhac O., Schuh A.
Key Points Targeted NGS of relapsed/refractory CLL reveals a high incidence of concurrent mutations that mostly affect the TP53, ATM, and SF3B1 genes. Concurrent mutations of the TP53, ATM, and/or SF3B1 genes confer short survival in patients with relapsed/refractory CLL.